Europlasma: New bond financing and postponement of 2025 accounts

On April 30, 2026, Europlasma announced a new €45 million bond financing over 36 months. This financing, in the form of bonds convertible into shares (OCABSA), could result in a dilution of more than 99% of the share capital. The Environmental Performance Financing fund is involved, and share conversions could exert downward pressure on the share price.

In parallel, Europlasma is postponing the publication of its 2025 financial statements. This delay will allow for the completion of ongoing audits, particularly those related to strategic operations planned for 2025, such as the integration of FDB Industries and the sale of its defense division. Publication is expected before the end of May 2026.